Payment overview · 2025
General Payments
$2,284.58
113 reported records · 14 companies
Healthcare provider profile · identity verified
George Shokri
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MARIETTA, OH · NPI 1851677074
Verified facts
What the public records show
CMS Open Payments records show George Shokri received $2,284.58 in general payments during 2025 across 113 reported records.
ABBVIE INC. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Nurtec Odt, Qulipta, Ubrelvy, Zavzpret.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rytary by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZAVZPRET as an associated drug or biological on 140787 records involving 33518 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zavzpret by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $518.57 | 22.7% | 29 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $316.18 | 13.8% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $265.98 | 11.6% | 18 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$259.51 | 11.4% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $192.27 | 8.4% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $167.98 | 7.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.67 | 6.3% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $109.83 | 4.8% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $86.00 | 3.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.25 | 2.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.22 | 2.6% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $47.23 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.49 | 1.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.40 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,284.58 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $390.92 | 24 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $369.78 | 22 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $316.18 | 18 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $292.82 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $265.98 | 18 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $192.27 | 9 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $167.98 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $164.15 | 10 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $144.67 | 6 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $105.59 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $87.58 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $86.00 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $74.12 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $65.25 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $60.22 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $47.23 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 66 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 53 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZAVZPRET zavzpret |
2025 | Zavzpret | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ZAVZPRET open payments reported associated product |
CMS Open Payments — General Payments 140787 supporting records · 33518 recipient NPIs · example record 1228794071 |
Zavzpret · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 199 | 74 |
| Ropinirole Hcl | Ropinirole Hcl | 173 | 71 |
| Rizatriptan | Rizatriptan Benzoate | 141 | 33 |
| Topiramate | Topiramate | 121 | 38 |
| Pregabalin | Pregabalin | 111 | 37 |
| Primidone | Primidone | 107 | 34 |
| Xcopri | Cenobamate | 103 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 34 |
| Levetiracetam | Levetiracetam | 97 | 35 |
| Aimovig Autoinjector | Erenumab-Aooe | 94 | 11 |
| Eliquis | Apixaban | 74 | 11 |
| Ubrelvy | Ubrogepant | 69 | suppressed |
| Botox | Onabotulinumtoxina | 66 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | 19 |
| Qulipta | Atogepant | 55 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 53 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 49 | 20 |
| Donepezil Hcl | Donepezil Hcl | 42 | 16 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Lacosamide | Lacosamide | 40 | 11 |
| Briviact | Brivaracetam | 39 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 37 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 14 |
| Rytary | Carbidopa/Levodopa | 35 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Prednisone | Prednisone | 28 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 11 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Radicava Ors | Edaravone | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Levetiracetam Er | Levetiracetam | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Zavzpret | Zavegepant Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Nayzilam | Midazolam | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,284.58 · 113 records | ABBVIE INC. | AMPLATZER AMULET, AMPYRA, AMYVID, BOTOX, Briviact, CREXONT, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, QULIPTA, Rystiggo, SKYCLARYS, Symbravo, TYSABRI, UBRELVY, VUMERITY, VYALEV, VYEPTI, Xeomin, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error